Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBO Scores 15% Rebate For All Part D Brand Drugs In Health Care Report

Executive Summary

The Congressional Budget Office has taken proposals for a required rebate on drugs for dual-eligible beneficiaries in Medicare Part D a step further by scoring a 15 percent rebate requirement for all brand drugs in the program

You may also be interested in...



Part D Rebates In Crosshairs Of HHS OIG Investigators

The HHS Office of Inspector General is planning to find out how much Medicare Part D could save by using Medicaid drug pricing

Part D Rebates In Crosshairs Of HHS OIG Investigators

The HHS Office of Inspector General is planning to find out how much Medicare Part D could save by using Medicaid drug pricing

House Bill Would Expand Rx Market, But Negatives Draw PhRMA's Protest

The House health care reform bill contains a number of provisions that would greatly expand the market for pharmaceuticals, but the bill seeks a number of financial concessions from pharmaceutical manufacturers, prompting a statement of protest from the industry association

Related Content

UsernamePublicRestriction

Register

PS050460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel